BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther. 2019;13:1-11. [PMID: 30587923 DOI: 10.2147/dddt.s172324] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Elzubeir A, Alam SM. Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’. World J Gastroenterol 2020; 26(44): 7085-7087 [PMID: 33311952 DOI: 10.3748/wjg.v26.i44.7085] [Reference Citation Analysis]
2 Jefferson B, Ali M, Grant S, Frampton G, Ploof M, Andry S, DeMorrow S, McMillin M. Thrombospondin-1 Exacerbates Acute Liver Failure and Hepatic Encephalopathy Pathology in Mice by Activating Transforming Growth Factor β1. Am J Pathol 2020;190:347-57. [PMID: 31734229 DOI: 10.1016/j.ajpath.2019.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 de Jong LA, van Schoonhoven AV, Hofstra HS, Postma MJ, van Hoek B. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. J Med Econ 2021;24:1149-63. [PMID: 34629016 DOI: 10.1080/13696998.2021.1983291] [Reference Citation Analysis]
4 Chu YY, Wang X, Dai HL. Update on pharmacotherapy of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 58-64 [DOI: 10.11569/wcjd.v29.i2.58] [Reference Citation Analysis]